Ml, conjugated monomer; M2, free monomer; Abi, first antibody; Ab2, second antibody; Agl, analyte; F, fluorophore CLIN. CHEM. 33/9, 1509-1516 (1987) Received April 10, 1987; accepted June 22, 1987. (8), and the use of microporous membranes as the solid phase, to mimic solution-phase kinetics by keeping the diffusion distances within the matrix of the membrane short (9).
Many different solid-phase-based immunoas8ays have been described in the literature (e.g., 1,2, and reviewed in 3, 4) . The solid phase can take the form of a microparticulate (e.g., latex beads), a molded surface (e.g., microtiter wells), or a filter membrane (e.g., cellulose acetate or polyvinylidene fluoride). Although versatile and easy to use, some such solid-phase immunoassays continue to be plagued by slow reaction kinetics and high nonspecific binding by the presence of an unstirred layer of solution at the surface of the solid phase, the Nernst layer (6, 7), which serves to limit the rate of diffusion of reactants from the bulk solution. Among the approaches to circumventing this problem are the use of ultrasound,
to reduce the thickness of the umstirred layer Received April 10, 1987; accepted June 22, 1987. (8) , and the use of microporous membranes as the solid phase, to mimic solution-phase kinetics by keeping the diffusion distances within the matrix of the membrane short (9).
In this investigation, we describe two novel immunoassay methods in which the solid phase is generated in situ after the specific binding reaction between antigen and antibody has occurred. Thus, the kinetic properties of the reactions approach those of reactants that are free to diffuse in solution. And, because the solid phase is not present throughout the imniunoreaction, the possibility of nonspecific binding is also minimized.
The first assay, which we call de novo polymerization, involves two antibodies-an antibody labeled with a polymerizable organic monomer, and a signal-labeled antibody ( Figure 1 ). After the specific binding between antigen and antibody has taken place, polymerization of the monomerlabeled antibody is initiated by means of a reaction involving free radicals. This results in the formation of insoluble polymer particles, the signal content of which is directly proportional to the amount of antigen in the sample.
The second assay involves thermal precipitation, taking advantage of a class of water-soluble polymers that exhibit different solubilities as a function of temperature (10) . Some of these polymers will reversibly precipitate upon heating above a characteristic temperature, the "lower critical solution temperature," for that polymer. In this assay we use an antibody labeled with such a reversibly soluble polymer and a signal-labeled antibody (Figure 2 ). After the specific binding reaction, we increase the temperature of the reac-Detect Particle -Associated Signal tion milieu above the critical solution temperature of the polymer, such that insoluble polymer particles are formed. Again, the signal content of the particles is directly proportional to the amount of antigen in the sample.
Here we describe several examples in which these techniques are used in enzyme and fluorescence inimunoassays of such diverse analytes as IgG, hepatitis B surface antigen (HBs Ag), and Chiamydia trachomatis.4 
Materials and Methods

Matenals
Preparatory Procedures
Synthesis of monomers.
We synthesized p-styrene sulfonyl chloride from sodium p-styrene sulfonate (Aldrich Chemical Co., Milwaukee, WI) and thionyl chloride. After extracting the mixture twice with benzene, drying it over magnesium sulfate, and concentrating by rotary evaporation, we analyzed the product by thin-layer chromatography, NMR, and mass spectrometry.
We synthesized the N-hydroxysuccimmide ester of 4-vinylbenzoic acid (Aldrich) from dicyclohexylcarbodiimide. We recrystallized the product once from methanol and analyzed it by NMR, mass spectrometry, and infrared spectroscopy.
We used isothiocyanatophenylacetylene (Aldrich) as received.
Conjugation of activated monomers to antibody. Styrene aulfonyl chloride, isothiocyanatophenylacetylene, and the ester of vinyl benzoate were conjugated to antibody via amino groups. We performed the conjugations with various ratios of monomer to protein in 0.29 molJL sodium carbonate Nonstandard abbreviations:
HBs Ag, hepatitis B surface antigen; NMR, nuclear magnetic resonance; PBS, phosphate-buffered saline; BSA, bovine serum albumin; pNTPAAm, poly-N-isopropylacrylamide; TEMED, N,N,N',N'-tetramethylethylenediainine; TMB, 3,3',5,5'-tetramethylbenzidene; ELISA, enzyme-linked immunoassay.
buffer (pH 9.3), incubating for 1 h at 37 #{176}C. We desalted the conjugates on Sephadex G-25 (Pharmacia) equilibrated in phosphate-buffered saline, pH 7.4, containing 10 mmol of NaH2PO4, 150 mmol of NaC1, and 0. #{149} Serial thermal precipitation. The reaction mixture was diluted to 20 mL with PBS and heated to 37#{176}C for 10 miii. The resulting suspension was centrifuged (4000 x g, 37#{176}C, 5 mm) and the supernate discarded. The precipitate was redissolved to 20 mL in ice-cold PBS and the cycle repeated twice more. After the third precipitation, the precipitate was dissolved to 2 mL in PBS and stored at 4#{176}C until needed.
#{149} Serial salt-induced precipitation. We added 12 mL of cold-saturated ammoniuin sulfate to the reaction mixture to bring the final concentration of ammonium sulfate to 14.3% of saturation.
The suspension was then centrifuged (10 mm, 2000 x g, 25#{176}C) and the supernate discarded. The precipitate was redissolved to 12 mL in PBS and the cycle was repeated twice more. The final precipitate was dissolved in 4 mL of PBS and desalted by chromatography on Sephadex G-25.
Synthesis of fluorescent conjugates. We synthesized ffuorescein conjugates according to the method of Goding (11) , using isomer II of fluorescein isothiocyanate (12) . Thiol groups were introduced into the antibody by reaction with S-acetylmercaptosuccinic anhydride (13) , and reactive maleimide groups were introduced into the phycoerythrin by using succinimidyl 4-(N-maleimidomethyl)cyclohexane-1-carboxylate (Pierce Chemical Co., Rockford, IL) (14) . After coupling thiolated antibody to the maleimidoester of phycoerythrin via a sulfoether linkage, we separated the resulting conjugate from free phycoerythrin by gel-ifitration chromatography on Sephacryl S-300, equilibrated in PBS containing 1 g of sodium azide per liter. The molar ratio of antibody to phycoerythrin was typically approximately 1.5:1.
Synthesis of antibody/enzyme conjugates.
We conjugated the enzyme horseradish peroxidase (EC 1.11.1.7) to antibody by the periodate method (15) and purified the resulting conjugates by ammonium sulfate precipitation and dialysis against PBS. They were stored in 500 g/L glycerol matrix until needed. Immediately before use, we diluted the conjugates to working strength in PBS, pH 7.4, containing phycoerythrmn-conjugated monoclonal antibody, 2C3, to the mu chain of 1gM (final concentration 45 .tg/mL), and prepared standards from mock serum reconstituted to contain a series of known concentrations of two myeloma proteins, IgG/kappa and IgMikappa. We analyzed the reaction mixture by multiparameter flow microfluorimetry, using a FACS N equipped with a 560-nm dichroic mirror to split the emission wavelengths.
To further separate the signals, a 580-nm long-pass ifiter was placed in front of the red photomultiplier tube, and a 540-nm short-pass filter in front of the green 
C. trachomatis
LGV . Incubate for 20 mm at room temperature, then heat to 45#{176}C to precipitate the polyner. Collect the precipitate by centriftigation, wash twice with hot (45 #{176}C) PBS, and develop and measure color as described in the preceding assay.
Results and DiscussIon
De Novo Polymerization
The key reagent in the de novo polymerization assay is the monomer-conjugated antibody. We synthesized a variety of different monomers, conjugated them to antibody, and evaluated their performance in an assay for human IgG. A schematic representation of a typical conjugation is shown for the monomer vinyl benzoate in Figure 3 . The number of monomers per antibody molecule was determined in each case by liquid chromatography and (or) isoelectric focusing of the immunoglobulun heavy and light chains, which had first been separated by electrophoresis in polyacrylamide gels containing sodium dodecyl sulfate. The latter method was particularly informative because it allowed us to determine which immunoglobulin chains were derivatized, as well as the extent of derivatization.
For each monomer tested, we carried out conjugations at several different ratios of monomer to antibody. The optimal ratio was determined on the basis of performance in the assay itself. The best conjugate was not always the most
CH2: CH-©-COOH
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Q However, because the conjugates were assayed in use, we could not discriminate whether this difference was due to loss of antigen-binding ability by the antibody or to loss of activity by the monomer at higher loadings.
As Figure 4 shows, there was considerable difference in performance between different conjugated monomers. This difference is thought to be due to differences in the efficiency of incorporation of the monomer-conjugated antibody into polymer, isothiocyanatophenylacetylene presumably being incorporated least efficiently and vinyl benzoate most efficiently. In actual fact, the percentage of monomer-conjugated antibody incorporated into polymer is quite low in all cases. This could indicate that a high proportion of the conjugated monomer is inactivated by the conjugation procedure or that it is sterically hindered and thus unavailable to participate in the polymerization reaction. In an effort to render the monomer more accessible, we used an avidinbiotin bridge between the monomer and the antibody, but the efficiency of incorporation was not substantially increased (data not shown). Neither did increasing the time of polymerization beyond about 20 mm significantly increase the extent of incorporation of monomer into polymer (data not shown).
As we expected, the polymer particles formed by this reaction were polydisperse, with smaller particle sizes predominating. The size distribution of the particles was not static, but changed as a function of time after the initiation of polymerization. If left long enough, the particles would eventually coalesce into a single large bead that could not be readily dispersed. Figure 5 shows a series of histograms corresponding to different concentrations of human IgG, as assayed by flow microfluorimetry.
The sensitivity (detection limit) of this assay is approximately 5 ng/mL (2 x 10" moIIL). Although accuracy has not been rigorously evaluated in this system, we find that the results consistently correlate with those by ELISA (data not shown). Recovery experiments have not been performed.
As illustrated in Table 1 of which fluorophore was used to label 3F6. We also used de novo polymerization to assay IgG and 1gM in a single sample, using a phycoerythrin-labeled antibody to report 1gM molecules and a fluoresceinated antibody to report IgG. In Figures 6 and 7 , the data from two such assays are presented as contour plots on 64 x 64 grids, each 64 dots representing four logs of fluorescence. The log scale has the effect of amplifying small differences in the amplitude of the signal near the origin, while minimizing the larger differences in amplitude; hence, even unlabeled particles show a measureable autofluorescence (Figure 6a To assess the effect of serum in this system, we added increasing amounts of pooled human serum, which had been stripped of IgG and 1gM by affinity chromatography, to the assay at two concentrations of analyte (1gM, 0 and 1 .tg/mL). We saw no effect on assay results even when serum represented as much as 20% of the total assay volume (data not shown). We do not have sufficient data at this time to say whether icteric, lipemic, or hemolyzed samples will be tolerated.
Thermal precipitation.
Polymers are known that precipitate either above or below a certain critical temperature; the former are said to exhibit a lower critical solution temperature, and the latter, an upper critical solution temperature. Our efforts have focused primarily on the former polymers, chiefly acrylamide and N-alkyl acrylamide polymers or copolymers.
That polymers with a lower critical solution temperature are reversibly soluble provides a dual advantage:
the efficiency of washing is maximized while dilution of the signal and sample is minimized. Ideally, the polymer is precipitated initially from a relatively small volume, to minimize dilution of the sample, and is redissolved in subsequent steps in a relatively large volume, to promote washing. Signal development can be carried out in either phasewhen the polymer is precipitated or when it is in solution.
The maximum concentration effect is achieved when signal development is carried out in the solid phase, which represents the smallest possible volume the polymer can occupy. However, if the signal is generated enzymatically, it may be desirable to carry out signal development in solution, because the rate of diffusion of the enzyme substrate into the precipitate may be rate-limiting.
In Figure 8 To be useful in an immunoassay, a polymer must have a critical solution temperature that is unaffected by the presence of substances commonly encountered in a biological fluid. Furthermore, given our primary interest in infectious disease testing, we also wanted to consider the effects of additives that might be used to solubilize the sample. Thus we examined the effects of serum, urine, detergents (ionic, non-ionic, and zwitterionic), and a variety of other substances, including ions, anticoagulants, chelating agents, and N-acetylcysteine (a sputum-solubilizing agent) on the critical solution temperature of the pNIPAAm polymer. None of these compounds caused a significant change in the critical solution temperature of the polymer over the range of concentrations in which they might be expected to be found in biological samples (data not shown here; see 16). Furthermore, the critical solution temperature of the polymer was unaffected by the conjugation of antibody to the polymer backbone, although the size of the particles that formed above the critical solution temperature was dependent on the degree of antibody substitution.
To prepare antibody conjugates of pNIPAAm, we copolymerized vinyl benzoate-conjugated antibody with NIPAAm monomers in various ratios and separated the resulting conjugates from unreacted monomer and monomer-conjugated antibody by serial precipitation or by gel filtration. If desired, the mixture could be further purified by chromatography on hydroxylapatite.
Under the appropriate conditions, antibody-conjugated polymer will bind to hydroxylapatite and can be eluted in a subsequent step by increasing the ionic strength (data not shown).
In addition to being thermally precipitable, pNIPAAm and copolymers thereof can be precipitated from solution by adding ammonium sulfate to 14%-20% of saturation, depending on the composition of the polymer. Because immunoglobulins do not precipitate at these salt concentrations, this is a convenient method of separating antibody-conjugated polymer from free antibody. Independent of the method of purification, we find the resulting conjugates to have an apparent molecular mass >106 Da, based upon their elution profIle from Sephacryl S-300. However, this is not likely to be an accurate representation of their molecular mass, given the dependence of such determinations on hydrodynamic properties of the polymer. We estimate the number of antibody molecules per polymer to be between one and three.
In Figure 9 , we compare the amount of fluorescence in solution before and after thermal precipitation of pNIPAAm These data compare favorably with those by ELISA-based methods, both in terms of sensitivity and performance time. Accuracy has not been rigorously evaluated with this system, but we find that the results correlate well with those by ELISA. In summary, we have described two novel immunoassay systems that combine the convenience of a solid phase with the superior reaction kinetics of the solution phase. Although much work remains to be done before the clinical utility of these assays can be established, we have shown that these assays are applicable to a variety of analytes, including macromolecular antigens such as HBs Ag and Chiamydia. We have described both immunoenzymometric and fluoroiinmunoassays and shown that both assay systems can be adapted for use with existing laboratory instrumentation.
